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Diversity of ATM gene variants: a
population-based genome data analysis for
precision medicine
Hisanori Fukunaga1,2,3* , Yasuyuki Taki3,4 and Kevin M. Prise1
Abstract
Background: Ataxia-telangiectasia (AT) is a rare autosomal recessive disorder that causes deficiency or dysfunction
of the ataxia-telangiectasia mutated (ATM) protein. Not only AT patients, but also certain ATM heterozygous
mutation carriers show a significantly reduced life expectancy due to cancer and ischemic heart disease; in
particular, female carriers having particular alleles have an increased risk of breast cancer. The frequency of such risk
heterozygotes at a population level remains to be fully determined, and evidence-based preventive medical
guidelines have not yet been established.
Methods: Using the 3.5KJPNv2 allele frequency panel of Japanese Multi Omics Reference Panel v201902, which
shows single-nucleotide variant (SNV) and insertion/deletion (INDEL) allele frequencies from 3552 Japanese healthy
individuals, we investigated the diversity of ATM gene variants.
Results: We detected 2845 (2370 SNV and 475 INDEL) variants in the ATM gene, including 1338 (1160 SNV and 178
INDEL) novel variants. Also, we found a stop-gained SNV (NC_000008.11:g.108115650G > A (p.Trp266*)) and a
disruptive-inframe-deletion (NC_000008.11:g. 108181014AAGAAAAGTATGGATGATCAAG/A (p.Ala1945_
Phe1952delinsVal) and two frameshift INDELs (NC_000008.11:g.108119714CAA/C (p.Glu376fs) and NC_000008.11:
g.108203577CTTATA/C (p.Ile2629fs)), which would be novel variants predicted to lead to loss of ATM functionality.
Conclusion: The combination of population-based biobanking and human genomics provided a novel insight of
diversity of ATM gene variants at a population level. For the advancement of precision medicine, such approach will
be useful to predict novel pathogenic/likely pathogenic variants in the ATM gene and to establish preventive
medical guidelines for certain ATM heterozygotes pertaining to their risk of particular diseases.
Keywords: Ataxia-telangiectasia mutated, Population-based biobank, Heterozygotes, Precision medicine, Whole-
genome reference panel
Introduction
Ataxia-telangiectasia (AT) is a rare autosomal recessive
disorder clinically characterized by cerebellar degener-
ation, immune-deficiency, radiation hypersensitivity, and
cancer predisposition. Also, metabolic disorders impli-
cated in cardiovascular and liver diseases are frequently
observed in adolescent AT patients [1]. The worldwide
prevalence of AT is estimated to be between 1 in 40,000
and 1 in 100,000 live births [2].
The ataxia-telangiectasia mutated (ATM) gene was first
reported in 1995 as the causative gene responsible for AT
[3]. Most AT patients lack functional ATM protein due to
missense or non-sense mutations in the ATM gene, which
result in truncated or unstable ATM variants [4]. The
ATM gene is located on chromosome 11q22-q23, span-
ning approximately 150 kb of genomic DNA, and encodes
a protein of 3056 amino acids which is a phosphoinositidyl
3-kinase (PI3K)-family kinase [5]. ATM forms dimers or
oligomers under non-stress conditions, and DNA damage
induces intermolecular autophosphorylation of Ser1981
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that causes dimer dissociation and initiates intracellular
ATM kinase activity [6]. In addition to Ser1981, other au-
tophosphorylation sites, Ser367, Ser1893, and Ser2996 are
physiologically important parts of the DNA damage re-
sponse [7, 8]. Also, ATM phosphorylates several proteins
involved in cell cycle checkpoint control, apoptosis, and
DNA repair, including p53, Chk2, BRCA1, RPAp34,
H2AX, SMC1, FANCD2, Rad17, Artemis, and Nbs1 [9].
Not only AT patients, but also certain ATM heterozy-
gous mutation carriers have a reduced life expectancy.
In 1987, Swift and co-workers reported that for hetero-
zygotes responsible for AT, the relative risk of cancer
was estimated to be 2.3 for men and 3.1 for women [10].
Furthermore, according to a systematic review in 2016,
siblings of AT patients who are heterozygous carriers of
pathogenic ATM gene mutations have a significantly in-
creased risk of cancer and ischemic heart disease (rela-
tive risk (RR) 1.7, 95% confidential interval (CI) 1.2–2.4),
and female heterozygotes having particular alleles have
an increased risk of breast cancer (RRwomen 3.0, 95%
CI 2.1–4.5) [11]; thus, certain ATM heterozygous muta-
tion carriers should be made aware of lifestyle factors
that contribute to the development of such diseases.
However, the accurate frequency of heterozygous car-
riers of pathogenic mutations in the ATM gene at a
population level, to date, remains to be determined, and
evidence-based preventive medical guidelines have not
yet been established [12]. From the point of view of pre-
cision medicine, appropriate approaches are immediately
needed for ATM heterozygotes pertaining to their risk of
particular diseases.
Methods
To address the issue, we used the 3.5KJPNv2 allele fre-
quency panel [13–16], which is a part of Japanese Multi
Omics Reference Panel version 201902 (Feb 2019, https://
jmorp.megabank.tohoku.ac.jp/201902/) released from the
Tohoku University’s Tohoku Medical Megabank
Organization (ToMMo) [17]. This population-based whole-
genome reference panel shows single-nucleotide variant
(SNV) and insertion/deletion (INDEL) allele frequencies
from 3552 Japanese healthy individuals. jMorp was originally
published in 2018, as a multi-omics database of metabolites
and proteins in plasma obtained from volunteers in ToMMo
[17]. From jMorp release 201806 (Jun 2018, https://jmorp.
megabank.tohoku.ac.jp/201806/), genomic variant data
have been added, and the version 201,902 (Feb 2019,
https://jmorp.megabank.tohoku.ac.jp/201902/) is where
allele frequencies of all the genomic variants can be exam-
ined through the web interface.
Although they previously used an original re-sequencing
workflow for the 1KJPN5 [13], 2KJPN, and 3.5KJPNv1, for
building the 3.5KJPNv2, ToMMo decided to use a more
common pipeline including the 1000 Genomes Project
[18] and gnomAD [19] algorithms to reduce technical
biases and to allow comparisons to other populations.
ToMMo customized three steps in the Genome Analysis
Toolkit (GATK) Best Practices workflow, which are widely
used in large-scale sequencing projects and recommend
post-alignment processing before variant calling [20]: (1)
the choice of the reference genome, (2) the use of base
quality score recalibration (BQSR), and (3) the joint geno-
typing step. Although the GATK Best Practices workflow
recommends that the BQSR step be carried out after the
mapping, ToMMo did not do so, but checked concord-
ance among two kinds of genotyping results: (i) genotyp-
ing results obtained after the incorporation of BQSR and
(ii) results obtained without BQSR. Thus, the allele fre-
quency panel, 3.5KJPNv2 of jMorp version 201902, can be
easily used to compare the allele frequencies of different
populations with the web interface.
The 3.5KJPNv2 is available at jMorp website, and the
raw data in Variant Call Format (VCF) format was also
registered at the NBDC Human Database (https://
humandbs.biosciencedbc.jp/en/) with accession code
hum0015.v3 by the National Bioscience Database Center
(NBDC) of the Japan Science and Technology Agency to
ensure accessibility, preservation, and stability of the
3.5KJPNv2 datasets [16]. Individual’s sequence data and
genotyping results from which allele frequency dataset is
constructed and validated are available upon request after
approval of the Ethical Committee and the Materials and
Information Distribution Review Committee of ToMMo.
In the present study, we accessed the raw data of the
3.5KJPNv2 allele frequency panel and investigated the allele
frequencies of ATM gene variations, with the assumption
of the Hardy-Weinberg equilibrium. Also, we investigated
novel variants, which are predicted to lead to loss of ATM
functionality based on their protein structures.
Results and discussion
As shown in Fig. 1a, with the 3.5KJPNv2 allele frequency
panel, we searched for the allele frequencies of ATM
gene variations and found 2845 (2370 SNV and 475
INDEL) variants in the given population, including 1338
(1160 SNV and 178 INDEL) novel variants, which have
not yet been assigned reference single-nucleotide poly-
morphism (SNP) ID numbers [21]. This result demon-
strates that, with the assumption of the Hardy-Weinberg
equilibrium, a large number of healthy individuals have
novel heterozygous variants in the ATM gene, indicating
that the ATM genetic diversity is greater than expected.
We found a novel stop-gained SNV in the ATM gene,
NC_000008.11:g.108115650G >A (p.Trp266*). As shown
in Fig. 1b, this SNV removes all the main identified do-
mains including the nuclear localization signal (NLS; ~aa
385 to 388), the leucine zipper (LZ; ~aa 1216 to 1241), the
FRAP/ATM/TRRAP (FAT; ~aa 1960 to 2566), the kinase
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(PI3-K; ~aa 2712 to 2962), and the FAT c-terminal
(FATC; ~aa 3024 to 3056) domains, which are physiolo-
gically important for the activation and regulation of
ATM kinase activity [9]. Also, this removes autophospho-
rylation sites, Ser367, Ser1893, Ser1981, and Ser2996,
which are significantly related to ATM protein functional-
ity. Taken together, the stop-gained SNV in the ATM
gene is predicted to be a novel loss-of-function variant.
Next, we detected a novel disruptive_inframe_deletion,
NC_000008.11:g.108181014AAGAAAAGTATGGATGAT-
CAAG/A (p.Ala1945_Phe1952delinsVal), and two frameshift
INDELs, NC_000008.11:g.108119714CAA/C (p.Glu376fs)
and NC_000008.11:g.108203577CTTATA/C (p.Ile2629fs).
Because of the dramatic changes of amino acid sequence
and three-dimensional structure, all the INDELs are
predicted to lead to loss of ATM functionality. Even NC_
000008.11:g.108203577CTTATA/C, although maintaining
more than 2500 normal amino acid sequence from the
N-terminal of ATM, removes normal C-terminal PI3-K
domain and autophosphorylation site Ser2996, which are
essential for ATM signaling in human cells.
To our knowledge, there is no previous study relating
to the clinical risk of these four variants. However, ac-
cording to the possible ATM functionality based on
their protein structures, certain ATM heterozygous mu-
tation carriers having these variants are likely to have a
reduced life expectancy. From the point of view of preci-
sion medicine, personalized preventive medical strategies
would be immediately needed.
Conclusion
In this study, we showed the diversity of ATM gene vari-
ants at a population level and found four novel variants
which are predicted to lead to loss of ATM functionality.
Further advancements in the combination of population-
based biobanking and human genomics are expected to
further uncover the genetic basis of AT patients and cer-
tain ATM heterozygotes who have a reduced life expect-
ancy. Also, for the advancement of precision medicine,
such approach will be useful to establish an evidence-
based guideline not only for AT patients but also for risk
ATM heterozygotes seeking preventive medical strategies.
Fig. 1 Novel variants predicted to lead to loss of ATM functionality. a A total of 2845 (2370 SNV and 475 INDEL) variants in the ATM gene has
confirmed, including 1338 (1160 SNV and 178 INDEL) novel variants which have not yet been assigned reference SNP ID numbers. b ATM is a
protein of 3056 amino acids. The phosphorylation sites (P) indicate the positions of serine residues, Ser367, Ser1893, Ser1981, and Ser2996 [6–8].
The NLS (~aa 385 to 388), the LZ (~aa 1216 to 1241), the FAT (~aa 1960 to 2566), the PI3-K (~aa 2712 to 2962), and the FATC ( ~aa 3024 to 3056)
domains are shown in orange, light green, green, blue, and violet respectively [9]. Novel variants predicted to lead to loss of ATM functionality
are indicated using red arrows: (1) stop-gained SNV, NC_000008.11:g.108115650G > A (p.Trp266*), (2) frameshift INDEL,
NC_000008.11:g.108119714CAA/C (p.Glu376fs), (3) disruptive-inframe-deletion INDEL, NC_000008.11:g.108181014AAGAAAAGTATGGATGATCAAG/A
(p.Ala1945_Phe1952delinsVal), (4) frameshift INDEL, NC_000008.11:g.108203577CTTATA/C (p.Ile2629fs)
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